New Targets for Therapy in Breast Cancer: Mammalian Target of Rapamycin (mTOR) Antagonists

Breast Cancer Research - United Kingdom
doi 10.1186/bcr927
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Mammalian Target of Rapamycin (mTOR; FRAP; RAFT1)

Science-Business eXchange
2010English

Targeting the Mammalian Target of Rapamycin (mTOR): A New Approach to Treating Cancer

British Journal of Cancer
Cancer ResearchOncology
2004English

Mammalian Target of Rapamycin (mTOR) Inhibition: Potential for Antiseizure, Antiepileptogenic, and Epileptostatic Therapy

Current Neurology and Neuroscience Reports
NeuroscienceNeurology
2012English

Mammalian Target of Rapamycin (mTOR) Pathways in Neurological Diseases

Biomedical Journal
Medicine
2013English

Regulation of Targets of mTOR (Mammalian Target of Rapamycin) Signalling by Intracellular Amino Acid Availability

Biochemical Journal
BiochemistryCell BiologyMolecular Biology
2003English

Mammalian Target of Rapamycin (mTOR) Inhibition in Advanced Bronchial Carcinoids

European Oncology and Haematology
OncologyHematology
2015English

Combination Therapy for Treating Breast Cancer Using Antiestrogen, ERA-923, and the Mammalian Target of Rapamycin Inhibitor, Temsirolimus

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2006English

Metformin Inhibits Mammalian Target of Rapamycin Dependent Translation Initiation in Breast Cancer Cells

Cancer Research
Cancer ResearchOncology
2007English

Mammalian Target of Rapamycin (mTOR) as a Potential Therapeutic Target in Pathological Ocular Angiogenesis

Biological and Pharmaceutical Bulletin
MedicinePharmacologyPharmaceutical Science
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy